B. Metzler seel. Sohn & Co. AG Sells 30,906 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

B. Metzler seel. Sohn & Co. AG lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 27.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 82,595 shares of the biopharmaceutical company's stock after selling 30,906 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Gilead Sciences were worth $7,629,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of GILD. Norges Bank acquired a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $1,789,254,000. Wellington Management Group LLP lifted its position in Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after acquiring an additional 11,665,593 shares in the last quarter. Pacer Advisors Inc. lifted its position in Gilead Sciences by 723.3% in the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock valued at $594,370,000 after acquiring an additional 5,653,075 shares in the last quarter. Raymond James Financial Inc. bought a new position in Gilead Sciences during the 4th quarter worth about $207,340,000. Finally, Point72 Asset Management L.P. raised its stake in shares of Gilead Sciences by 350.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company's stock valued at $193,274,000 after purchasing an additional 1,793,145 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Bank of America increased their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Oppenheimer lifted their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a report on Tuesday, March 4th. Piper Sandler increased their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $105.12.

Remove Ads

Gilead Sciences Price Performance

GILD traded down $5.14 during trading on Friday, hitting $107.25. 12,918,179 shares of the stock traded hands, compared to its average volume of 7,351,764. The business has a 50 day moving average price of $107.30 and a 200 day moving average price of $95.89. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The company has a market cap of $133.54 billion, a price-to-earnings ratio of 289.86, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, March 14th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.95%. Gilead Sciences's payout ratio is 854.05%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 142,180 shares of the business's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. The trade was a 52.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 302,785 shares of company stock worth $30,503,250 in the last three months. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.